Investment in Equity Method Investee - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Schedule Of Equity Method Investments [Line Items]
Operating expenses	$ 39,344,843	$ 24,545,414	$ 101,228,098	$ 66,817,819
Net loss			77,785,576	$ 49,244,511
Deferred revenue	45,304,459		45,304,459		$ 58,407,407
Oerth
Schedule Of Equity Method Investments [Line Items]
Cash commitment	$ 49,400,000		$ 49,400,000
Future grant of incentive units to service providers, percentage	15.00%		15.00%
Deferred revenue	$ 24,700,000		$ 24,700,000
Equity method investments	0		0
Additional losses	0		0
Oerth | Equity Method Investment, Nonconsolidated Investee or Group of Investees
Schedule Of Equity Method Investments [Line Items]
Operating expenses	2,300,000		4,900,000
Net loss	2,300,000		4,900,000
Bayer LP | Oerth
Schedule Of Equity Method Investments [Line Items]
Cash commitment	$ 56,000,000.0		$ 56,000,000.0
Ownership interest in joint venture	50.00%		50.00%